These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 25729475)
21. A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis. Ganguli S; DeLeeuw P; Satapathy SK Hepat Med; 2019; 11():159-178. PubMed ID: 31814783 [TBL] [Abstract][Full Text] [Related]
22. The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease. Perla FM; Prelati M; Lavorato M; Visicchio D; Anania C Children (Basel); 2017 Jun; 4(6):. PubMed ID: 28587303 [TBL] [Abstract][Full Text] [Related]
23. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease. Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769 [TBL] [Abstract][Full Text] [Related]
24. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. Ferolla SM; Armiliato GN; Couto CA; Ferrari TC World J Hepatol; 2015 Mar; 7(3):559-65. PubMed ID: 25848479 [TBL] [Abstract][Full Text] [Related]
25. Molecular pathways of nonalcoholic fatty liver disease development and progression. Bessone F; Razori MV; Roma MG Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320 [TBL] [Abstract][Full Text] [Related]
26. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. Yki-Järvinen H Curr Opin Clin Nutr Metab Care; 2010 Nov; 13(6):709-14. PubMed ID: 20842026 [TBL] [Abstract][Full Text] [Related]
27. Non-alcoholic fatty liver disease: The diagnosis and management. Abd El-Kader SM; El-Den Ashmawy EM World J Hepatol; 2015 Apr; 7(6):846-58. PubMed ID: 25937862 [TBL] [Abstract][Full Text] [Related]
28. [Steatosis and steatohepatitis in diabetic patient]. Hůlek P; Dresslerová I Vnitr Lek; 2011 Apr; 57(4):364-7. PubMed ID: 21612059 [TBL] [Abstract][Full Text] [Related]
29. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. Abenavoli L; Milic N; Di Renzo L; Preveden T; Medić-Stojanoska M; De Lorenzo A World J Gastroenterol; 2016 Aug; 22(31):7006-16. PubMed ID: 27610012 [TBL] [Abstract][Full Text] [Related]
31. Nonalcoholic fatty liver disease - current status and future directions. Demir M; Lang S; Steffen HM J Dig Dis; 2015 Oct; 16(10):541-57. PubMed ID: 26406351 [TBL] [Abstract][Full Text] [Related]
32. Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis. Garcia-Martinez I; Alen R; Rada P; Valverde AM Front Med (Lausanne); 2020; 7():395. PubMed ID: 32850903 [TBL] [Abstract][Full Text] [Related]
33. Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium. Purohit V; Russo D; Coates PM Alcohol; 2004 Aug; 34(1):3-8. PubMed ID: 15670659 [TBL] [Abstract][Full Text] [Related]
35. Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application. Xu Y; Guo W; Zhang C; Chen F; Tan HY; Li S; Wang N; Feng Y Front Pharmacol; 2020; 11():601. PubMed ID: 32477116 [TBL] [Abstract][Full Text] [Related]
36. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870 [TBL] [Abstract][Full Text] [Related]
37. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Dietrich P; Hellerbrand C Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181 [TBL] [Abstract][Full Text] [Related]
38. Fatty liver without a large "belly": Magnified review of non-alcoholic fatty liver disease in non-obese patients. Yousef MH; Al Juboori A; Albarrak AA; Ibdah JA; Tahan V World J Gastrointest Pathophysiol; 2017 Aug; 8(3):100-107. PubMed ID: 28868179 [TBL] [Abstract][Full Text] [Related]